IT security and risk management often ignore or underestimate the human factor (psychological, behavioural, societal, organisational and economic aspects) in the identification of cyber-risks, their quantitative economic impact and the costs of countermeasures. Cyber-attacks can harm intangible assets like reputation, IPR, expertise, and know-how. And there is severe imbalance between the efficiency of attacks and inadequate defences, due in part to the lack of quantitative information for decision makers to prioritise security investments. To foster a culture of risk management by an individual organisation or a complete sector, HERMENEUT answers: What is the real fallout of a data compromise and the long-run consequences on associated assets? What are the losses for intangible assets? Do other type of attacks (beyond data breach) severely impact intangible and tangible assets? HERMENEUT assesses vulnerabilities of organisations and corresponding tangible and intangible assets at risk, taking into account the business plans of the attacker, the commoditisation level of the target organisations, the exposure of the target and including human factors as well as estimating the likelihood that a potential cyber-attack exploits identified vulnerabilities. HERMENEUT’s cyber-security cost-benefit approach combines integrated assessment of vulnerabilities and their likelihoods with an innovative macro- and micro-economic model for intangible costs, delivering a quantitative estimation of the risks for an organisation or a business sector and investment guidelines for mitigation measures. 11 partners from 6 countries deliver an innovative methodology and advanced macro- and micro-economic models and make it available to the European research community. HERMENEUT implements its innovations in a decision support tool, tested with 2 users in healthcare and an IPR-intensive industry.

The GRACE integrated solution aims to transform the healthcare ecosystem by providing essential knowledge and innovative public-private partnership for (1) reorganizing healthcare services (2) with embedded innovative technologies and tools, helping identifying and overcoming barriers and gaps that are now hindering CVD management, ensuring a seamless continuum of care and optimized care pathways. Our vision is that introducing effective health technology and interventions is economically, societally and environmentally sustainable if and only accompanied by a substantial healthcare service re-organization. Accordingly, GRACE will focus on an end-to-end clinical pathway CVD, considering an holistic view of the patient and optimizing healthcare services leveraging on advanced technological solutions. GRACE intervention will be multifold aiming at: (1) guiding strategic policies, (2) drive market innovation, and (3) foster effective healthcare delivery practices in CVD, generating value for patients, healthcare workers and system. GRACE will enable early and personalized interventions, fostering coordination of multidiscipline healthcare teams, triggering more intense and person-specific management using innovative technologies, AI and digital solutions for early detection of red flags, promoting patient empowerment, while comprehensively containing CVD risk factors and burden. A multidisciplinary consortium of experienced and competitive partners will implement this vision and implement the proposed solution in a novel multidiscipline manner.

IMPROVE will use Patient Generated Health Data (PGHD) gathered via m-health and e-health technologies to gain improved insights into the real-life behavior of, and challenges faced by, patients of all ages with complex, chronic diseases and comorbidities. Already today, a wealth of patient and citizen information is available, but fragmented, and therefore not coming to its full utility and value. These personal data will complement and improve existing approaches for Patient-Centered Outcome Measures beyond those currently available in state-of-the-art platforms. The IMPROVE platform that the consortium will build will enable the smart use of patient input and patient generated evidence to 1) advance the role of patient preference and patient experience in the context of treatment selection, 2) improve medical device design based on patient preferences and experiences, and 3) facilitate faster market entry of patient-centric and cost-effective advanced integrated care solutions. Improved clinical adoption of Value Based Health Care, and enhanced return on research and innovation investments will be demonstrated in different care settings across the EU, for 10 use cases in at least 5 different disease areas (e.g., ophthalmology, oncology, cardiovascular disease, chronic inflammation, and neurology). The use cases will be conducted using a large variety of implementation strategies, building on a design thinking approach, to optimally test the innovative framework of data gathering and translation into controlled change and action. In addition, a significant contribution from implementation science is planned to reach out to all stakeholders that are relevant for this initiative and maximise the impact to IMPROVE healthcare provision.

BRECISE is a Public-Private Partnership Project, co-funded by the Innovative Health Initiative (IHI) of the European commission aiming at creating a collaborative ecosystem to accelerate the clinical validation of Next-Generation Sequencing (NGS)-based, multi-modality Artificial Intelligence (AI) oncology biomarkers and related technologies. By addressing technical and regulatory challenges, the consortium unites diverse expertise and resources to validate novel prostate and bladder cancer biomarkers, ensuring their efficacy and clinical utility. This initiative aligns with the goal of advancing precision medicine in oncology, ultimately improving patient outcomes and streamlining personalized cancer care. BRECISE's primary objective is to enhance biomarker-driven approaches for patient risk stratification, disease progression prediction, and treatment response assessment, within the framework of precision medicine. The project addresses the current challenge of limited access to clinically validated prognostic and predictive biomarkers in oncology. By providing healthcare professionals with NGS-based, multi-modality AI oncology biomarkers, BRECISE aims to enable precise disease risk assessment and informed treatment selection, contributing to more personalized and effective patient care. The impact of BRECISE is transformative, aiming to revolutionize risk assessment and treatment selection in oncology, facilitating the implementation of precision medicine. This will significantly reduce unnecessary and ineffective treatments, optimizing patient care and minimizing side effects. The validated biomarker technologies empower researchers to develop safer and more effective personalized treatments, advancing precision medicine. These advancements will enhance the competitiveness of European health industries, positioning them at the forefront of innovation and healthcare excellence. Overall, BRECISE is expected to significantly improve patient outcomes, enhance healthcare efficiency, and bolster the global standing of European health industries.